Development of a Homogeneous Trastuzumab-Triptolide Conjugate for Targeted Therapy of HER2-Overexpressing Ovarian Cancer.

Fadayomi IE, Jangan M, Varghese D, Pires E, McCullagh J, Richardson A, Brunt AM, Li WW

DOI: 10.1021/acs.bioconjchem.6c00171
Published: 2026 Aug 21
Container: Bioconjugate chemistry
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1021/acs.bioconjchem.6c00171,
  title = {Development of a Homogeneous Trastuzumab-Triptolide Conjugate for Targeted Therapy of HER2-Overexpressing Ovarian Cancer.},
  author = {Fadayomi IE and Jangan M and Varghese D and Pires E and McCullagh J and Richardson A and Brunt AM and Li WW},
  year = {2026},
  journal = {Bioconjugate chemistry},
  doi = {10.1021/acs.bioconjchem.6c00171},
  url = {https://doi.org/10.1021/acs.bioconjchem.6c00171}
}

RIS

TY  - JOUR
TI  - Development of a Homogeneous Trastuzumab-Triptolide Conjugate for Targeted Therapy of HER2-Overexpressing Ovarian Cancer.
AU  - Fadayomi IE
AU  - Jangan M
AU  - Varghese D
AU  - Pires E
AU  - McCullagh J
AU  - Richardson A
AU  - Brunt AM
AU  - Li WW
PY  - 2026
JO  - Bioconjugate chemistry
DO  - 10.1021/acs.bioconjchem.6c00171
UR  - https://doi.org/10.1021/acs.bioconjchem.6c00171
ER  -

APA

IE, F., M, J., D, V., E, P., J, M., A, R., AM, B., & WW, L. (2026). Development of a Homogeneous Trastuzumab-Triptolide Conjugate for Targeted Therapy of HER2-Overexpressing Ovarian Cancer.. Bioconjugate chemistry. https://doi.org/10.1021/acs.bioconjchem.6c00171

Source records

pubmed · retrieved 2026-09-26T06:56:01.605Z